Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cogstate Ltd ( (AU:CGS) ) has issued an announcement.
Cogstate Ltd has announced an extension of its share buyback program, initially set to conclude on November 10, 2025. This move indicates the company’s ongoing commitment to managing its capital structure and potentially enhancing shareholder value. By extending the buyback, Cogstate may be aiming to bolster its market position and signal confidence in its financial health, which could have positive implications for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners in delivering electronic clinical outcome assessment solutions. Cogstate’s offerings include quality assurance services for study endpoints, advanced analytics, and scientific consulting, serving biopharmaceutical companies, academic institutions, physicians, and patients worldwide.
YTD Price Performance: 161.37%
Average Trading Volume: 252,584
Technical Sentiment Signal: Buy
Current Market Cap: A$463.4M
For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.